about
Directed expression of dominant-negative p73 enables proliferation of cardiomyocytes in miceAdvances in the management of heart failure: the role of ivabradineEndotoxin-activated cultured neonatal rat cardiomyocytes express functional surface-associated interleukin-1alphaTrans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatEffect of inflammatory mediators on cardiovascular function.Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies.Ivabradine in Combination with Metoprolol Improves Symptoms and Quality of Life in Patients with Stable Angina Pectoris: A post hoc Analysis from the ADDITIONS Trial.Performance of Sokolow-Lyon index in detection of echocardiographically diagnosed left ventricular hypertrophy in a normal Eastern German population - results of the CARLA study.Direct inhibition, but indirect sensitization of pacemaker activity to sympathetic tone by the interaction of endotoxin with HCN-channels.Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactions.Inhibition of cardiac pacemaker channel hHCN2 depends on intercalation of lipopolysaccharide into channel-containing membrane microdomains.Mechanisms of infective endocarditis: pathogen-host interaction and risk states.Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC coculturesImpaired regulation of cardiac function in sepsis, SIRS, and MODS.Septic cardiomyopathy - A not yet discovered cardiomyopathy?The alteration of autonomic function in multiple organ dysfunction syndrome.Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome.Impaired chemoreflex sensitivity in adult patients with multiple organ dysfunction syndrome--the potential role of disease severity.Proteome analysis of myocardial tissue following ischemia and reperfusion--effects of complement inhibition.Activation of AP-1 contributes to the beta-adrenoceptor-mediated myocardial induction of interleukin-6.Analysis of complex physiological systems by information flow: a time scale-specific complexity assessment.Role of LDL receptor-related protein (LRP) in coronary atherosclerosis.Assessing inflammageing.The impact of impaired renal function on mortality in patients with acutely decompensated chronic heart failure.Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome.The ageing heart: influence of cellular and tissue ageing on total content and distribution of the variants of elongation factor-2.Inhibition of p53 after acute myocardial infarction: reduction of apoptosis is counteracted by disturbed scar formation and cardiac rupture.Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups.Decreased beating rate variability of spontaneously contracting cardiomyocytes after co-incubation with endotoxin.Endotoxin impairs the human pacemaker current If.Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor.Treatment with bone morphogenetic protein 2 limits infarct size after myocardial infarction in mice.Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.In memoriam of Dr. Heinz Rupp: associate editor of the Canadian Journal of Physiology and Pharmacology.Optimal maximum tracking rate of dual-chamber pacemakers required by children and young adults for a maximal cardiorespiratory performance.Erratum to "Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concep
P50
Q24314598-E849D03E-2DB1-49E5-94A3-19165BF62D92Q28072418-D95CC79C-68B3-4BE5-A943-F49EA4D7DE47Q28583222-218CEE2B-34FE-429E-A147-CC7469C332FCQ30313154-BB08DB09-1EDA-40D8-B9ED-1B3A05665CA3Q30313894-4A47AE60-0228-498F-BB1C-DB30E7DF95BFQ30314307-34017B24-1EFD-4653-BBF6-39B75CBC76E0Q30316010-E4CD3EDD-AD40-4686-B97D-1450A9A48397Q30316384-BBA7B5D5-22B2-421D-85EA-E0AAB8802372Q30316590-B3458927-74D9-47B3-B348-E46EEEC98F21Q30316766-94D91E45-C501-4098-8AD0-91BF32D6F819Q30316932-6282E668-C30B-4EFC-8E5D-DD43F7773873Q30317615-178EDC8C-0881-452E-8D13-F187EDC3CB5DQ30317657-258F449B-4B25-42F5-9B69-1688A7AA33D4Q30318221-96FEABB4-9FA6-4C08-8B8F-4E913DBBD4DDQ30318280-C516F5B0-AACD-44C1-819D-B74E72191323Q30318384-B1A39D4D-A5FD-43B5-AC4B-882CB5E83808Q30318772-CCC22F90-9EA6-4EBA-8EF2-75FD3CDA24B8Q30319125-C92A3BE2-18ED-47A6-9FBD-4BDCB8D2ED2BQ30319484-514965D2-AAB1-47D4-AB86-E4C312717D55Q30319674-DD00DEF8-551A-4398-A841-4C0D043903F2Q30320030-3E67F36D-78D4-4F68-9B00-A27A4270D76DQ30320530-AA579E86-115F-4343-90E2-0581816AF985Q33260603-A2F6CF63-443B-44FF-94F7-BBD1EBACFE35Q36072891-9116E026-9FD2-48A5-BDEE-F6D63F177A69Q36568573-71663570-99D2-4648-8CC1-C24ECB13C757Q40610005-01134099-ED17-4303-BB81-2A70FD662C20Q42513173-6F158A5D-9EDF-44C5-8D45-51AF88F6E0A6Q43190668-96447F74-3568-4718-B38E-A247C949AD70Q43630557-4892D3A1-F2C4-43D0-9EA7-10CDC1AEB781Q44151293-231C5403-86C7-44B2-97B5-D07F934BF487Q44958914-8F5BE075-4189-415A-B07B-B606210DC07BQ46691588-7CDF6A45-B6F2-4760-8CE8-FC9F8EB87292Q46817336-C1E4D80B-70BB-4D9A-8566-199EEDA06515Q46842063-CB936AD1-8F97-4F1F-AA7B-3052A36C8B57Q46856188-6C0A302B-C6D8-4D8B-872A-6AC5051AEB74Q47256718-E534FB8B-29BC-416D-9A51-46713EF87A75Q48066135-9F23AB16-2A77-4828-A7CE-9F192B622BF1Q48077856-93170EFE-3F0C-4543-ACDD-12C4488D0309Q48951265-3252A29D-8017-4114-9087-EBB3909FE281Q49642595-D46B299F-25DF-4D99-B928-A4E80E07E9D5
P50
name
Ursula Müller-Werdan
@en
type
label
Ursula Müller-Werdan
@en
prefLabel
Ursula Müller-Werdan
@en